GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Forward PE Ratio

Alliance Pharma (LSE:APH) Forward PE Ratio : 7.84 (As of Apr. 29, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Forward PE Ratio?

Alliance Pharma's Forward PE Ratio for today is 7.84.

Alliance Pharma's PE Ratio without NRI for today is 11.65.

Alliance Pharma's PE Ratio for today is 0.00.


Alliance Pharma Forward PE Ratio Historical Data

The historical data trend for Alliance Pharma's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Forward PE Ratio Chart

Alliance Pharma Annual Data
Trend 2015-12 2016-12 2017-12 2018-12 2019-03 2021-12 2022-12 2023-12 2024-04
Forward PE Ratio
12.11 11.15 15.17 14.22 14.10 17.01 9.14 7.25 7.84

Alliance Pharma Semi-Annual Data
2015-12 2016-03 2016-06 2016-09 2016-12 2017-03 2017-06 2017-09 2017-12 2018-03 2018-06 2018-09 2018-12 2019-03 2021-09 2021-12 2022-03 2022-06 2022-09 2022-12 2023-03 2023-06 2023-09 2023-12 2024-03
Forward PE Ratio 12.11 12.08 11.49 11.12 11.15 11.83 13.14 11.66 15.17 14.25 20.79 12.45 14.22 14.10 16.72 17.01 18.15 17.27 8.29 9.14 13.79 10.49 8.33 7.25 8.91

Competitive Comparison of Alliance Pharma's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alliance Pharma's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's Forward PE Ratio falls into.



Alliance Pharma Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Alliance Pharma  (LSE:APH) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Alliance Pharma Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alliance Pharma (LSE:APH) Business Description

Traded in Other Exchanges
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).